Rare Disease Genetic Testing

Rare Disease Genetic Testing Market Outlook

The global Rare Disease Genetic Testing market is projected to reach USD 10 billion by 2033, with a compound annual growth rate (CAGR) of 11% from 2025 to 2033. The growth of this market is driven by a combination of factors including the increasing prevalence of rare diseases, advancements in genetic testing technologies, and growing awareness among healthcare providers and patients regarding the importance of early diagnosis and targeted treatments. Additionally, favorable government initiatives and funding aimed at promoting rare disease research are expected to significantly contribute to market growth. The integration of artificial intelligence and machine learning into genetic testing processes also presents opportunities for enhanced accuracy and efficiency, thereby further driving the market forward.

Growth Factor of the Market

One of the primary growth factors for the Rare Disease Genetic Testing market is the rising incidence of rare genetic disorders worldwide. As the medical community becomes more aware of the genetic basis of these diseases, the demand for precise testing solutions continues to escalate. Furthermore, advances in technology, particularly in genomics and bioinformatics, have made genetic testing more accessible and efficient. The increasing investment in research and development by both private and public sectors is also bolstering the market, as it leads to the discovery of new tests and treatment options for rare conditions. In addition, regulatory bodies are beginning to recognize the importance of rare disease research, resulting in incentives for companies that develop innovative testing methods. The growing patient advocacy and support groups are actively campaigning for awareness and funding for rare diseases, which translates into a favorable environment for market expansion.

Key Highlights of the Market

• The global Rare Disease Genetic Testing market is growing at a CAGR of 11% from 2025 to 2033.
• Rising incidences of rare diseases and genetic disorders are driving demand for testing solutions.
• Technological advancements are leading to more efficient and accurate testing methods.
• Favorable government initiatives and funding support are facilitating market growth.
• Increased awareness among healthcare professionals and patients about the importance of genetic testing.

By Test Type

Diagnostic Testing:

Diagnostic Testing holds a significant share of the Rare Disease Genetic Testing market as it is crucial for confirming the presence of a specific genetic disorder in patients. This type of testing often involves the use of advanced genomic sequencing technologies, allowing for a clear identification of mutations that may contribute to rare diseases. As healthcare providers increasingly advocate for early and precise diagnosis, the demand for diagnostic testing is anticipated to grow substantially. The effectiveness of such tests in guiding treatment decisions further enhances their value, leading to an uptick in their adoption among physicians and specialists. Additionally, continuous innovations in diagnostic methods are expected to improve testing accuracy and turnaround times, making such solutions more appealing to both healthcare providers and patients.

Carrier Testing:

Carrier Testing is another vital segment of the Rare Disease Genetic Testing market, primarily aimed at individuals who may be carriers of specific genetic disorders without showing symptoms themselves. This testing is particularly important for couples planning a family, as it helps in assessing the risk of passing on inherited conditions to their children. As awareness about genetic risks during pregnancy increases, the usage of carrier testing is expected to rise. Advances in technology have enabled the development of more comprehensive carrier panels, allowing for the simultaneous testing of multiple genes associated with rare diseases. This efficiency not only saves time but also reduces the financial burden on families by offering more information in a single test, thereby catalyzing market growth.

Prenatal Testing:

Prenatal Testing has become increasingly integral to the Rare Disease Genetic Testing market, as expectant parents seek to understand the genetic health of their unborn children. Utilizing non-invasive techniques such as cell-free fetal DNA testing, prenatal testing can identify various genetic disorders early in pregnancy, allowing for informed decision-making. The growing acceptance of genetic testing during pregnancy, fueled by advancements in technology and enhanced accuracy, is anticipated to drive this segment significantly. Additionally, as public awareness of the importance of genetic health continues to rise, more healthcare providers are likely to recommend prenatal testing as part of standard maternal care. The ability of prenatal testing to offer peace of mind to parents also contributes to its growing popularity and subsequent market growth.

Newborn Screening:

Newborn Screening is a critical component of the Rare Disease Genetic Testing market, designed to identify genetic disorders shortly after birth. This early detection not only facilitates timely intervention and treatment but also significantly improves health outcomes for affected infants. As healthcare systems worldwide emphasize preventive care, the implementation of comprehensive newborn screening programs has gained traction. The growing recognition of the importance of early diagnosis in managing rare diseases is expected to fuel demand for newborn screening tests. Additionally, advancements in testing technologies are expanding the range of disorders that can be detected through newborn screening, thereby enhancing its utility and acceptance among both healthcare providers and parents.

Preimplantation Testing:

Preimplantation Testing plays a pivotal role in the Rare Disease Genetic Testing market, particularly for couples undergoing in vitro fertilization (IVF) procedures. This testing allows for the genetic assessment of embryos before implantation, enabling prospective parents to select embryos free from specific genetic disorders. The rising prevalence of infertility issues, coupled with a growing desire for healthy offspring, is likely to drive demand for preimplantation testing services. Furthermore, as the technology behind preimplantation genetic testing advances, it is becoming more accessible and reliable, contributing to its increasing adoption. This segment is poised for significant growth as more fertility clinics integrate preimplantation testing into their offerings, thereby enhancing the overall IVF experience for patients.

By Technology

Microarray:

Microarray technology is a prominent method utilized in the Rare Disease Genetic Testing market, allowing for the simultaneous analysis of thousands of genes. This technology has proven invaluable for identifying genetic variations associated with various rare diseases. Its high throughput and scalability make it particularly advantageous for large-scale genetic studies and research. As healthcare providers increasingly recognize the benefits of microarray testing in diagnosing complex genetic disorders, its adoption is expected to rise. The ability to quickly process large amounts of genetic data facilitates timely decision-making for patient management, further driving the demand for this technology. Additionally, ongoing advancements in microarray technologies continue to enhance their accuracy and reliability, solidifying their position in the genetic testing landscape.

Sequencing:

Sequencing technology is at the forefront of the Rare Disease Genetic Testing market, particularly with the advent of next-generation sequencing (NGS). This method allows for comprehensive genomic analysis, enabling the identification of a wide array of genetic mutations associated with rare diseases. The precision and depth of data generated through sequencing make it a preferred choice among healthcare providers for diagnosing complex genetic conditions. As NGS becomes more affordable and accessible, its utilization in clinical practice is expected to increase significantly. The continuous development of sequencing technologies is poised to enhance diagnostic capabilities, ultimately improving patient outcomes. Moreover, the integration of bioinformatics tools with sequencing data is likely to further streamline analysis and interpretation, boosting its adoption in various healthcare settings.

Polymerase Chain Reaction:

Polymerase Chain Reaction (PCR) is a well-established technique in the Rare Disease Genetic Testing market, primarily used for amplifying small segments of DNA to facilitate detailed genetic analysis. PCR's robustness and sensitivity make it an ideal choice for detecting specific mutations associated with rare diseases. As healthcare practitioners increasingly rely on precise and targeted testing methods, the adoption of PCR is expected to remain strong. Moreover, advancements in PCR technologies, including real-time PCR and digital PCR, have enhanced its applicability in clinical settings. The ability to provide rapid results with high sensitivity positions PCR as a critical tool in the diagnosis and management of genetic disorders, contributing to its sustained growth in the market.

Biochemical Testing:

Biochemical Testing represents another significant segment within the Rare Disease Genetic Testing market, focusing on analyzing metabolic pathways and enzyme activity to identify genetic disorders. This approach is particularly useful for detecting inborn errors of metabolism, which are often classified as rare diseases. As healthcare providers recognize the importance of understanding metabolic profiles in diagnosing rare conditions, the demand for biochemical testing is anticipated to increase. The integration of biochemical tests with genetic analysis enhances the overall diagnostic accuracy and offers a comprehensive view of a patient’s genetic health. Moreover, the continuous advancements in biochemical testing methodologies are expected to improve detection rates and lead to better patient management, further propelling market growth.

Other Technologies:

In addition to the aforementioned technologies, various other methods are being utilized in the Rare Disease Genetic Testing market. These may include technologies such as fluorescence in situ hybridization (FISH), mass spectrometry, and CRISPR-based techniques, which offer unique advantages in specific testing scenarios. The diversity of available technologies allows healthcare providers to select the most appropriate method based on the nature of the suspected disease and the individual patient's needs. As innovation continues to drive the development of new testing technologies, the market is likely to witness increased options, enhancing the ability to diagnose and manage rare diseases effectively. The ongoing evolution of these technologies is essential for meeting the growing demand for accurate and timely genetic testing solutions.

By Disease Type

Inherited Rare Diseases:

Inherited Rare Diseases constitute a significant focus within the Rare Disease Genetic Testing market, as these conditions are passed down through genetic inheritance. The identification of mutations associated with inherited disorders is crucial for effective diagnosis and management. With advancements in genetic testing, it has become possible to screen for a multitude of inherited diseases, leading to earlier diagnosis and intervention. Increased awareness and education regarding the importance of genetic testing among both healthcare providers and patients are further propelling the demand for testing solutions in this segment. As the understanding of the genetic basis of these diseases continues to evolve, the market for inherited rare disease testing is expected to expand rapidly.

Non-Inherited Rare Diseases:

Non-Inherited Rare Diseases represent another essential segment of the Rare Disease Genetic Testing market, encompassing conditions that arise from spontaneous mutations rather than genetic inheritance. The complexity and variability of non-inherited diseases pose unique challenges in diagnostics, making genetic testing critical for accurate identification. As research advances in understanding the mechanisms behind these diseases, the demand for specialized testing solutions is anticipated to grow. The increasing recognition of the role of genetic factors in environmental and lifestyle-related conditions is also contributing to the expansion of this segment. This ongoing evolution in understanding non-inherited rare diseases is likely to drive market growth as more providers incorporate genetic testing into diagnostic workflows.

By User

Hospitals:

Hospitals are a key user segment within the Rare Disease Genetic Testing market, serving as primary healthcare facilities where patients are diagnosed and treated. The integration of genetic testing into hospital settings is an essential component of modern medical practice, enabling timely and accurate diagnosis of rare diseases. With advancements in genetic testing technologies, hospitals are increasingly incorporating these tests into their diagnostic protocols. This trend is likely to continue as healthcare systems prioritize personalized medicine approaches that leverage genetic information to guide treatment decisions. Additionally, hospitals are becoming more equipped to manage complex cases involving rare diseases, thereby driving the demand for genetic testing services.

Diagnostic Laboratories:

Diagnostic Laboratories play a critical role in the Rare Disease Genetic Testing market by providing specialized testing services to healthcare providers and patients. These laboratories are equipped with advanced technologies and expertise needed to conduct comprehensive genetic testing, including sequencing and microarray analysis. As demand for accurate and timely testing continues to rise, diagnostic laboratories are expanding their capabilities and offerings. The increasing reliance on these facilities for genetic testing is fostering collaboration with hospitals and clinics, thereby driving market growth. Furthermore, the competitive landscape among diagnostic laboratories is encouraging innovation and improvements in testing methodologies, ensuring the availability of high-quality testing solutions.

Research Institutes:

Research Institutes represent a vital user group within the Rare Disease Genetic Testing market, focusing on the development of new testing methods and the exploration of genetic underpinnings of rare conditions. These institutions often lead the charge in innovative research, contributing to the advancement of genetic testing technologies and methodologies. As the scientific community continues to uncover the complexities of rare diseases, the collaboration between research institutes and healthcare providers is expected to enhance the accuracy and efficiency of genetic testing. This synergy not only furthers our understanding of genetic disorders but also facilitates the translation of research findings into clinical practice. The ongoing investment in research initiatives focused on rare diseases is likely to bolster the demand for genetic testing in this segment.

Others:

Other users within the Rare Disease Genetic Testing market include various stakeholders such as public health organizations, genetic counseling services, and private testing companies. These entities play crucial roles in promoting awareness and accessibility of genetic testing services for rare diseases. Public health organizations often advocate for the inclusion of genetic testing in standard health assessments, thereby increasing the demand for such tests. Additionally, genetic counseling services provide essential support to individuals and families navigating the complexities of genetic risks and testing options. The involvement of private testing companies also enhances market competition, driving innovation and improving service quality. As awareness of genetic testing continues to grow, these user segments are expected to contribute significantly to overall market growth.

By Region

North America is expected to dominate the Rare Disease Genetic Testing market, accounting for approximately 40% of the global market share by 2033. The region's robust healthcare infrastructure, high levels of investment in research and development, and the presence of numerous key players in the genetic testing space contribute to this leading position. Additionally, the growing prevalence of genetic disorders and the rising awareness of the importance of early diagnosis and personalized treatment options are further driving market growth in North America. A CAGR of over 12% is projected for this region, indicating a strong upward trajectory fueled by technological advancements and increased access to genetic testing services.

Europe is projected to be the second-largest market for Rare Disease Genetic Testing, holding approximately 30% of the global market share by 2033. The increasing focus on rare diseases among European healthcare authorities, coupled with significant investments in genetic research, is expected to drive market growth in this region. The adoption of genetic testing in clinical practice is rising, supported by government initiatives aimed at improving healthcare outcomes for patients with rare diseases. Additionally, the growing collaboration between hospitals and diagnostic laboratories is enhancing the accessibility of testing services across Europe, further contributing to the market's expansion. Moreover, with the increasing awareness and acceptance of genetic testing among healthcare providers and patients, Europe is set to experience substantial growth in the coming years.

Opportunities

The Rare Disease Genetic Testing market presents numerous opportunities for growth, particularly in the realm of technological advancements. As new testing methods continue to emerge, there exists a significant opportunity for companies to innovate and develop more efficient, accurate, and cost-effective solutions. The integration of artificial intelligence and machine learning into genetic testing processes is one such opportunity, enabling quicker data analysis and improved interpretation of results. Furthermore, the expansion of telemedicine and digital health solutions offers avenues for remote genetic counseling and testing services, making genetic testing more accessible to patients, especially in underserved regions. As the market for genetic testing expands, companies that are quick to adapt and embrace these technological trends are likely to gain a competitive edge and capture a larger market share.

Additionally, there is a growing focus on patient-centric care and personalized medicine within the healthcare industry. This shift presents opportunities for genetic testing companies to collaborate with healthcare providers and research institutions to develop tailored testing solutions that meet specific patient needs. The increasing recognition of the importance of genetic information in the treatment of rare diseases is driving demand for targeted therapies and personalized treatment plans. Furthermore, as public awareness of rare diseases and the role of genetic testing in diagnosis and management continues to rise, there is an opportunity for companies to engage in educational initiatives that promote the benefits of genetic testing for both healthcare providers and patients. By positioning themselves as leaders in patient education and support, these companies can enhance their brand reputation and foster long-term partnerships within the healthcare ecosystem.

Threats

The Rare Disease Genetic Testing market faces several threats that could impact its growth trajectory. One significant challenge is the issue of regulatory compliance and the evolving landscape of genetic testing regulations. As governments and regulatory bodies implement stricter guidelines, companies may face increased costs and complexities in bringing their products to market. Furthermore, the rapid pace of technological advancements necessitates continuous adaptation from companies to remain compliant with emerging standards. Failure to navigate this regulatory landscape effectively could hinder market entry and limit growth opportunities for genetic testing providers.

Another potential threat stems from the competitive nature of the market, with numerous players vying for market share. This intense competition can lead to price wars, which may ultimately compromise the quality of testing services and products. Additionally, with the rise of direct-to-consumer genetic testing services, there is a risk of consumers opting for less comprehensive testing solutions that may not provide accurate or reliable information. This trend poses a threat to traditional healthcare providers and diagnostic laboratories that depend on the credibility and thoroughness of their testing methods. As the market continues to evolve, companies must remain vigilant in maintaining the quality and integrity of their testing services to mitigate these threats effectively.

Competitor Outlook

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Invitae Corporation
• GeneDx
• 23andMe, Inc.
• Fulgent Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics Incorporated
• PerkinElmer, Inc.
• MDxHealth SA
• Centogene AG

The competitive landscape of the Rare Disease Genetic Testing market is characterized by a mix of established players and emerging companies that are continually innovating to meet the growing demand for genetic testing solutions. Established firms like Illumina, Inc. and Thermo Fisher Scientific, Inc. dominate the market with their extensive portfolios of advanced genetic testing technologies and services. These companies leverage their strong research and development capabilities to introduce cutting-edge testing methodologies that cater to the needs of healthcare providers and patients alike. Their robust distribution networks and established relationships with healthcare institutions further reinforce their competitive positioning in the market.

Emerging companies such as Invitae Corporation and GeneDx are also making significant strides in the Rare Disease Genetic Testing market by focusing on niche areas and offering specialized testing services. These companies are driven by a commitment to improving diagnostic accuracy and providing comprehensive genetic information to patients and healthcare providers. Their focus on personalized medicine and patient-centric approaches allows them to differentiate themselves in a competitive market landscape. Moreover, the rise of direct-to-consumer genetic testing services, exemplified by companies like 23andMe, is reshaping the competitive dynamics of the market. These companies are empowering consumers with access to genetic testing while simultaneously posing a challenge to traditional providers.

In conclusion, the Rare Disease Genetic Testing market is poised for substantial growth, driven by advancements in technology, increasing awareness, and a strong focus on personalized medicine. As the market evolves, companies must navigate various challenges while seizing opportunities to enhance their offerings and expand their reach. The competitive landscape will continue to be shaped by both established and emerging players, each striving to deliver innovative and reliable genetic testing solutions to meet the needs of patients and healthcare providers alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GeneDx
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Centogene AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 MDxHealth SA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 23andMe, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Illumina, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 PerkinElmer, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Invitae Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Myriad Genetics, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Fulgent Genetics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Agilent Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bio-Rad Laboratories, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Quest Diagnostics Incorporated
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Laboratory Corporation of America Holdings (LabCorp)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Rare Disease Genetic Testing Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Rare Disease Genetic Testing Market, By Test Type
    • 6.2.1 Diagnostic Testing
    • 6.2.2 Carrier Testing
    • 6.2.3 Prenatal Testing
    • 6.2.4 Newborn Screening
    • 6.2.5 Preimplantation Testing
  • 6.3 Rare Disease Genetic Testing Market, By Technology
    • 6.3.1 Microarray
    • 6.3.2 Sequencing
    • 6.3.3 Polymerase Chain Reaction
    • 6.3.4 Biochemical Testing
    • 6.3.5 Other Technologies
  • 6.4 Rare Disease Genetic Testing Market, By Disease Type
    • 6.4.1 Inherited Rare Diseases
    • 6.4.2 Non-Inherited Rare Diseases

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Rare Disease Genetic Testing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Rare Disease Genetic Testing market is categorized based on

By Test Type

• Diagnostic Testing
• Carrier Testing
• Prenatal Testing
• Newborn Screening
• Preimplantation Testing

By Technology

• Microarray
• Sequencing
• Polymerase Chain Reaction
• Biochemical Testing
• Other Technologies

By Disease Type

• Inherited Rare Diseases
• Non-Inherited Rare Diseases

By User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Invitae Corporation
• GeneDx
• 23andMe, Inc.
• Fulgent Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics Incorporated
• PerkinElmer, Inc.
• MDxHealth SA
• Centogene AG